The largest baby-care specialised company, Johnson & Johnson (NYSE:JNJ), announced the introduction of its campaign called “Share the Language of Love”. It is aimed at assisting less-privileged children enjoy the natural joys of childhood. The leading heath and baby care corporation would host the campaign by encouraging the mothers to contribute their children’s unused items to the less-fortunate ones. The company, in this noble cause, will be partnered by a leading India-based NGO named Goonj. The company undertook this campaign because it understands emotional needs of any child. Johnson & Johnson (NYSE:JNJ), net profit margin is 20.90% and weekly performance is -0.33%. On last trading day company shares ended up $100.58. Analysts mean target price for the company is $104.84. Johnson & Johnson (NYSE:JNJ), distance from 50-day simple moving average (SMA50) is 2.83%.
On May 05, 2014, Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), announced its financial results for the first quarter ended March 31, 2014, and provided a corporate update. The Company reported a net loss of $4.5 million, or $(0.17) per share (basic and diluted), for the first quarter of 2014 compared with a net loss of $5.6 million, or $(0.39) per share (basic and diluted), for the first quarter of 2013. Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), fell 0.88% in last trading session and ended the day on $15.81. Intra-Cellular Therapies, Inc. (NASDAQ: ITCI), quarterly performance is -5.89%.
Heron Therapeutics Inc (NASDAQ:HRTX), a specialty pharmaceutical company, announced that it has selected HTX-011, a unique combination product utilizing its proprietary Biochronomer™ polymer-based drug delivery platform, as the lead product candidate for its post-surgical pain program. HTX-011 is designed to slowly release the local analgesic agent bupivacaine and the NSAID meloxicam locally at the site of the surgery over 3-5 days. Heron Therapeutics Inc (NASDAQ:HRTX), shares moved up 7.21% in last trading session and was closed at $11.74, while trading in range of $10.74 – 12.38. Heron Therapeutics Inc (NASDAQ:HRTX), year to date (YTD) performance is 30.44%.
On May 15, 2014, Biostar Pharmaceuticals Inc (NASDAQ:BSPM), announced its financial results of the first quarter ended March 31, 2014. Revenue for the first quarter of 2014 increased 9.0% to approximately $13.2 million compared to $12.1 million for the first quarter of 2013. The increase is mainly attributable to the increase in sales volume of other Aoxing products and Weinan products and the addition of 4 new products at Shaanxi Weinan. The increase in sales volume is mainly due to the positive image spread by the hospital using our products. Our sales prices didn’t change much in the first quarter of 2014. Biostar Pharmaceuticals Inc (NASDAQ:BSPM), ended the last trading day at $1.40. Company weekly volatility is calculated as 9.04% and price to cash ratio as 1.89. Biostar Pharmaceuticals Inc (NASDAQ:BSPM), showed a positive weekly performance of 5.14%.
Bristol-Myers Squibb Co (NYSE:BMY) is geared up to participate in the UBS Health Care Conference. Executive VP and CCO, Giovanni Caforio will represent BMY in the conference. He will also make a formal presentation at 3 p.m., and the webcast of the same can be accessed through its official website. Further, all interested parties can also access the presentation material too. Bristol-Myers Squibb Co (NYSE:BMY), net profit margin is 17.70% and weekly performance is -4.69%. On last trading day company shares ended up $48.78. Analysts mean target price for the company is $54.76. Bristol-Myers Squibb Co (NYSE:BMY), distance from 50-day simple moving average (SMA50) is -5.07%.